Entera Bio Ltd. ENTX 深 沪
等待开盘 08-05 09:30:00 美东时间
2.05
+0.100
+5.13%
华盛通- 最 高2.1394
- 今 开1.99
- 成交量 15.98万股
- 最 低 1.99
- 昨 收 1.95
- 总市值 9317.70万
- 52周最高 2.79
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 1.5006
- 委 比 28.44%
- 总股本 4545.22万
- 历史最高 10.16
- 量 比 0.26
- 振 幅 7.66%
- 历史最低 0.472
- 每 手 1
- 风险率 0.25%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Entera Bio Advances EB613 with FDA Approval
The latest update is out from Entera Bio ( ($ENTX) ). On July 28, 2025, Entera ...
07-28 19:59
Entera Bio Receives FDA Agreement To Support EB613 NDA Filing With Single 24-Month Global Phase 3 Study In Postmenopausal Osteoporosis, Using Total Hip BMD As Primary Endpoint And Vertebral Fracture Incidence As Key Secondary
Entera Bio Ltd. (NASDAQ:ENTX), a leader in the development of oral peptides and protein replacement therapies, announced today that in a written response to a Type A meeting request, the U.S. Food and Drug Administration
07-28 19:32
Entera Bio Receives FDA Agreement on BMD as Primary Endpoint for EB613 Registrational, Phase 3 Study in Post-Menopausal Women with Osteoporosis
Entera Bio announced that the FDA has agreed to support the NDA filing for EB613, an oral osteoanabolic treatment for postmenopausal osteoporosis, with a single Phase 3 study. The study will use change in total hip BMD as the primary endpoint, marking a shift from traditional fracture-based primary endpoints. The company highlights EB613 as the first oral, daily anabolic tablet aiming to address the unmet need for an alternative to injectable tre...
07-28 11:30
OPKO Health and Entera Bio Announce Abstract on PK/PD of Oral GLP-2 Tablet for the Treatment of Short Bowel Syndrome Selected for 2025 ESPEN Congress
OPKO Health 和 Entera Bio 宣布，他们关于短肠综合征治疗的新型口服 GLP-2 类似物的研究摘要，被选中在 2025 年欧洲临床营养与代谢学会年会上展示。该疗法结合了 OPKO 的长效 GLP-2 激动剂和 Entera 的 N-Tab™ 技术，为短肠综合征患者提供更便捷的口服选择，目前唯一获批的 GLP-2 激动剂需每日注射。摘要强调了口服形式的潜在优势，如提高患者依从性及个性化治疗的可能。短肠综合征是一种罕见、可能危及生命的吸收障碍性疾病，影响约 3 万名美国和欧盟患者，市场规模庞大。OPKO 和 Entera 的合作旨在通过创新技术改善这类患者的治疗方案。
07-08 12:00
Entera Bio Data for EB613 Effects on Trabecular and Cortical Bone in Post-Menopausal Women with Osteoporosis Selected for Oral Presentation at ASBMR 2025 Annual Meeting
Entera Bio Ltd. announced that new data on the dual actions of EB613, a once-daily oral PTH(1-34) tablet for postmenopausal women with osteoporosis, has been selected for an oral presentation at the ASBMR 2025 Annual Meeting in Seattle. The Phase 2 study showed EB613 significantly increased bone mineral density (BMD) and demonstrated dual effects on bone formation and resorption. EB613 aims to address the treatment gap for high-risk osteoporosis ...
06-26 12:00
OPKO Health And Entera Bio Say New Pharmacologic And Pharmacokinetic In Vivo Data For Investigational Oral OPK-88006 Tablet Treatment Selected For Presentation At ENDO 2025 Annual Meeting
OPKO Health, Inc. (NASDAQ:OPK) and Entera Bio Ltd. (NASDAQ:ENTX) ("Entera") today announced that new pharmacologic and pharmacokinetic in vivo data for investigational oral OPK-88006 tablet treatment has been selected
06-25 20:12
OPKO Health and Entera Bio Abstract for First-in-Class Dual GLP-1/Glucagon Tablet Candidate for Patients with Obesity and Metabolic Disorders Selected for Presentation at the ENDO 2025 Annual Meeting
OPKO Health和Entera Bio宣布，其研究性口服药物OPK-88006在ENLO 2025会议上展示新数据。该药结合GLP-1和胰高血糖素，设计为每日口服或每周注射，用于肥胖及相关代谢病。双方计划今年向FDA提交IND申请，并开展1期临床试验。
06-25 12:00
Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors
Entrada Therapeutics has appointed Maha Radhakrishnan, M.D., to its Board of Directors. Dr. Radhakrishnan brings extensive experience in global drug development, which will support Entrada's clinical progress, particularly in its Duchenne muscular dystrophy programs.
06-03 11:00
Entera Bio files $100M mixed securities shelf
Entera Bio (NASDAQ:ENTX) filed $100M mixed securities shelf Filing More on Entera Bio Entera Bio GAAP EPS of -$0.06 beats by $0.01 Entera Bio GAAP EPS of -$0.25 beats by $0.03, revenue of $0.18M beats...
05-31 04:12
Entera Bio Q1 EPS $(0.06) Beats $(0.07) Estimate, Sales $42.00K
Entera Bio (NASDAQ:ENTX) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.07) by 14.29 percent. This is a 20 percent decrease over losses of $(0.05) per share from the same
05-10 04:09
